Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64926 | 0.77 | — | — | |
| SCHEMBL30945055 | 0.75 | CYP3A4 (0.42) | SMN1; SMN2ALDH1A1MAPTNISCHCYP2D6 | |
| Hydrochloric Acid SCHEMBL311521 | 0.75 | CYP3A4 (0.42) | SMN1; SMN2KDM4EALDH1A1MAPTNISCH | |
| Acetamide SCHEMBL9934071 | 0.75 | CCNC (0.37) | KDM4EALDH1A1CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL28058914 | 0.73 | ALDH1A1 (0.47) | SMN1; SMN2KDM4EALDH1A1MAPTTDP1 | |
| Formaldoxime SCHEMBL4910460 | 0.71 | CYP3A4 (0.37) | SMN1; SMN2KDM4EALDH1A1NISCHCYP2D6 | |
| SCHEMBL135343 | 0.70 | LMNA (0.57) | SMN1; SMN2KDM4EALDH1A1MAPTTDP1 | |
| Hydrochloric Acid SCHEMBL5379309 | 0.70 | ALDH1A1 (0.59) | SMN1; SMN2KDM4EALDH1A1MAPTTDP1 | |
| Hydrochloric Acid SCHEMBL28743794 | 0.70 | ALDH1A1 (0.59) | SMN1; SMN2KDM4EALDH1A1MAPTTDP1 | |
| Hydrochloric Acid SCHEMBL28930619 | 0.70 | ALDH1A1 (0.59) | SMN1; SMN2KDM4EALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116368-B2 | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto | PFIZER INC. (US) | 2024-10-15 | — | — | US | disclosed |
| CN-112888691-B | Pyrrolo [2,3-d ] pyrimidine tosylate, crystalline forms thereof, and related methods and intermediates for the preparation thereof | 辉瑞公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-112888691-B | Pyrrolo [2,3-d ] pyrimidine tosylate, crystalline forms thereof, and related methods and intermediates for the preparation thereof | 辉瑞公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2020084435-A1 | PYRROLO[2,3-D]PYRIMIDINE TOSYLATE SALT, CRYSTALLINE FORM THEREOF AND MANUFACTURING PROCESS AND INTERMEDIATES THERETO | PFIZER INC. (US) | 2020-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116368-B2 | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto | DCTPP1, TPMT, ATIC | SMN1; SMN2 3851/4885KDM4E 2378/4885ALDH1A1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.